$1.48 Billion is the total value of Cormorant Asset Management, LP's 64 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARQL | Exit | ARQULE INC | $0 | – | -292,095 | -100.0% | -0.07% | – |
| QTRX | Exit | QUANTERIX CORP | $0 | – | -54,945 | -100.0% | -0.08% | – |
| OMER | Exit | OMEROS CORPcall | $0 | – | -181,700 | -100.0% | -0.16% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -194,274 | -100.0% | -0.18% | – |
| MGTX | Exit | MEIRAGTX HOLDGIN PLC | $0 | – | -238,579 | -100.0% | -0.19% | – |
| ASNS | Exit | ARSANIS INC | $0 | – | -1,861,702 | -100.0% | -0.35% | – |
| CFRX | Exit | CONTRAFECT CORP | $0 | – | -2,905,638 | -100.0% | -0.36% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -296,712 | -100.0% | -0.36% | – |
| REPL | Exit | REPLIMUNE GROUP INC | $0 | – | -467,792 | -100.0% | -0.38% | – |
| NKTR | Exit | NEKTAR THERAPEUTICScall | $0 | – | -250,000 | -100.0% | -0.67% | – |
| ZGNX | Exit | ZOGENIX INCcall | $0 | – | -250,000 | -100.0% | -0.74% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCput | $0 | – | -184,000 | -100.0% | -1.43% | – |
| GTHX | Exit | G1 THERAPEUTICS INC | $0 | – | -994,287 | -100.0% | -1.55% | – |
| TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -884,916 | -100.0% | -1.84% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -3,481,471 | -100.0% | -3.02% | – |
| TSRO | Exit | TESARO INC | $0 | – | -900,000 | -100.0% | -5.42% | – |
| TSRO | Exit | TESARO INCcall | $0 | – | -1,253,300 | -100.0% | -7.56% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| APELLIS PHARMACEUTICALS INC | 26 | Q1 2024 | 8.6% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| ROCKET PHARMACEUTICALS, INC | 25 | Q1 2024 | 2.4% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rapport Therapeutics, Inc. | June 20, 2024 | 1,283,673 | - |
| CytomX Therapeutics, Inc. | May 13, 2024 | 5,750,000 | - |
| TScan Therapeutics, Inc. | April 29, 2024 | 2,500,000 | - |
| Immuneering Corp | April 15, 2024 | 561,128 | - |
| Ventyx Biosciences, Inc. | March 21, 2024 | 3,670,000 | - |
| Corbus Pharmaceuticals Holdings, Inc. | March 18, 2024 | 2,025,000 | - |
| 89bio, Inc.Sold out | February 14, 2024 | 0 | - |
| Aerovate Therapeutics, Inc.Sold out | February 14, 2024 | 0 | - |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 2,550,000 | - |
| Ambrx Biopharma, Inc. | February 14, 2024 | 8,725,040 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.